Recruiting

Blood Pressure Goals

Sponsor:

UCLA

Code:

NCT07910773

Conditions

End Stage Kidney Disease (ESKD)

Hypertension (HTN)

Peritoneal Dialysis (PD)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Target systolic blood pressure <120 mmHg.

Target systolic blood pressure <140 mmHg

Study Details

Brief summary:

The GOAL-BP pilot study will help determine whether a study comparing two blood pressure goals can be carried out in adults with end-stage kidney disease and high blood pressure who receive peritoneal dialysis. The main questions it aims to answer are whether eligible patients can be recruited for the study.

Researchers will compare two goals for the top blood pressure number (systolic blood pressure): below 120 mmHg versus below 140 mmHg.This pilot study will help plan a larger trial in the future.

Participants will:

  • Be assigned by chance to one of the two blood pressure goals.
  • Have their blood pressure measured at clinic visits about every two weeks.
  • Work with their kidney doctor on recommended changes to fluid management, peritoneal dialysis treatment, or blood pressure medicines to reach their assigned goal.
  • Be part of the study for about four and a half months.

Conditions

End Stage Kidney Disease (ESKD)

Hypertension (HTN)

Peritoneal Dialysis (PD)

Study ID

NCT07910773

Start date

Oct 30, 2026

Status verified date

Nov, 2026

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age ≥ 18 years.
  • Undergoing regular PD for treatment of ESKD.
  • On PD for ≥ 4 months. (We do not plan to enroll patients within the first 3 months of PD initiation because there can be large fluctuations in volume status and BP readings before patient coming into more of a steady state. We then require participants to have at least 1 month of BP data to allow calculation of an average pre-enrollment BP for screening for study entry.)
  • Diagnosis of HTN defined as being on antihypertensive medications or having routine clinic SBP ≥ 140 mmHg averaged over prior one month to screening.
  • Able to measure brachial BP.

Exclusion Criteria:

  • Planned transplant or HD transition < 4.5 months (the duration of study).
  • Estimated life expectancy < 4.5 months (also determined by asking the treating nephrologist).
  • Participation in another clinical trial that may affect BP management.
  • Pregnancy, anticipated pregnancy, or breastfeeding as this will limit the use of certain antihypertension medications in the study and pose additional risks to the patient and many pregnant patients are transitioned over to hemodialysis.
  • Incarceration or institutionalized living which may prohibit measurement of home BP.
  • Presence of a condition or abnormality that, in the opinion of the study team or treating nephrologist, would compromise the safety of the patient or the quality of the data.

Study Design

Enrollment

10 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: Intervention

Target systolic blood pressure <120 mmHg

other: Control

Target systolic blood pressure <140 mmHg

Interventions

Target systolic blood pressure <120 mmHg.

The target SBP <120 mmHg will be operationalized as SBP 100-119 mmHg in the intervention arm.

For volume control, the patient's dry weight target will be adjusted downward and will be attempted to be achieved through greater PD ultrafiltration, dietary fluid/salt restriction, or diuretics.

Once patients are deemed euvolemic based on the assessment of the treating nephrologist, antihypertensive medications will be added or adjusted in a standardized sequence: priority is given to angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs) due to data about this class of agents being shown to better preserve residual kidney function. Other medications are recommended to be added as indicated to maintain SBP <120 mmHg in the interventional arm.

If SBP were <100 mmHg at one visit or <105 mmHg at two consecutive visits, BP medications will be reduced to keep SBP in the range of 100 to 119 mmHg, to avoid hypotensive episodes.

Target systolic blood pressure <140 mmHg

The target SBP <140 mmHg will be operationalized as SBP 130-139 mmHg. For volume control, the patient's dry weight target will be adjusted downward and will be attempted to be achieved through greater PD ultrafiltration, dietary fluid/salt restriction, or diuretics. Once patients are deemed euvolemic based on the assessment of the treating nephrologist, antihypertensive medications will be added or adjusted in a standardized sequence: priority is given to angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs) due to data about this class of agents being shown to better preserve residual kidney function. Other medications are recommended to be added as indicated to maintain <140 mmHg in the control arm. If SBP were <130 mmHg at one visit or <135 mmHg at two consecutive visits, BP medications will be tapered/discontinued to keep SBP in the range of 130 to 139 mmHg.

Primary outcome measure

  • Feasibility of enrolling participants [ Time Frame: 4.5 months ]

Central Contacts and Locations

Central contacts

Kashvi Gupta, MD, MPH

734-546-4545Kashvi.Gupta@ucsf.edu

Locations

Satellite Healthcare - Daly City

Recruiting

San Francisco, California, United States, 94014

Contacts

Kashvi Gupta, MD, MPH

734-546-4545kashvi.gupta@ucsf.edu

Satellite Healthcare - San Francisco Geary

Recruiting

San Francisco, California, United States, 94118

Contacts

Kashvi Gupta, MD, MPH

734-546-4545kashvi.gupta@ucsf.edu

More Information

Sponsor

University of California, San Francisco

Last update posted

Nov 6, 2026

Last verified

Nov, 2026

Keywords

  • Target blood pressure
  • Peritoneal dialysis
  • End stage kidney disease
  • Hypertension

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-07. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-11-06. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.